News

Tempus received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead ECGs for signs associated with pulmonary hypertension.

Tempus’ multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis.

CHICAGO, July 30, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026.

Tempus AI, Inc. announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment.

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth

Findings from the multi-center Articulate Pro study show Paige Prostate improves diagnostic consistency, accelerates turnaround times, and reduces laboratory workloads

Tempus AI, Inc. (NASDAQ: TEM) will report its second quarter 2026 financial results on Thursday, July 30, 2026, and host a conference call and webcast at 4:30 p.m. ET.

CHICAGO, June 25, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma, one of the rarest and most aggressive cancers.

Tempus announced the successful multi-center validation of its FDA-cleared ECG-AF software for predicting the one-year risk of atrial fibrillation, published in Heart Rhythm.

Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 2:00 p.m. ET on Monday, June 8.